中国科学院机构知识库网格
Chinese Academy of Sciences Institutional Repositories Grid
首页 机构 成果 学者
  
  1. CAS IR Grid
机构
采集方式
内容类型
发表日期
学科主题
筛选

浏览/检索结果: 共18条，第1-10条 帮助

条数/页： 排序方式：
Structure-based development of potent and selective type-II kinase inhibitors of RIPK1 期刊论文  OAI收割
ACTA PHARMACEUTICA SINICA B, 2024, 卷号: 14, 期号: 1, 页码: 319-334
作者:  Qin, Ying;  Li, Dekang;  Qi, Chunting;  Xiang, Huaijiang;  Meng, Huyan
  |  收藏  |  浏览/下载：6/0  |  提交时间：2024/03/06
Discovery of 10H-Benzo[b]pyrido[2,3-e][1,4]oxazine AXL Inhibitors via Structure-Based Drug Design Targeting c-Met Kinase 期刊论文  OAI收割
JOURNAL OF MEDICINAL CHEMISTRY, 2022, 页码: 15
作者:  Zhan, Zhengsheng;  Ji, Yinchun;  Su, Haixia;  Fang, Chen;  Peng, Xia
  |  收藏  |  浏览/下载：30/0  |  提交时间：2023/04/10
Discovery of a highly potent kinase inhibitor capable of overcoming multiple imatinib-resistant ABL mutants for chronic myeloid leukemia (CML) 期刊论文  OAI收割
EUROPEAN JOURNAL OF PHARMACOLOGY, 2021, 卷号: 897
作者:  Lu, Tingting;  Cao, Jiangyan;  Zou, Fengming;  Li, Xixiang;  Wang, Aoli
  |  收藏  |  浏览/下载：39/0  |  提交时间：2021/04/26
Virtual Screening for Type II B Inhibitors of B-Raf(V600E) Kinase 期刊论文  OAI收割
CURRENT COMPUTER-AIDED DRUG DESIGN, 2020
作者:  Qiu, Kai-Xiong;  Zhang, Wen;  Yu, Fang;  Li, Wei;  Sun, Zhong-Wen
  |  收藏  |  浏览/下载：12/0  |  提交时间：2021/01/05
Discovery and characterization of a novel highly potent and selective type II native and drug-resistant V299L mutant BCR-ABL inhibitor (CHMFL-ABL-039) for Chronic Myeloid Leukemia (CML) 期刊论文  OAI收割
CANCER BIOLOGY & THERAPY, 2019, 卷号: 20, 期号: 6, 页码: 877-885
作者:  Wu, Jiaxin;  Wang, Aoli;  Li, Xixiang;  Chen, Cheng;  Qi, Ziping
  |  收藏  |  浏览/下载：76/0  |  提交时间：2019/11/27
Discovery of 4-((N-(2-(dimethylamino)ethyl)acrylamido)methyl)-N-(4-methyl-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)phenyl)benzamide (CHMFL-PDGFR-159) as a highly selective type II PDGFR alpha kinase inhibitor for PDGFR alpha driving chronic eosinophilic leukemia 期刊论文  OAI收割
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2018, 卷号: 150, 期号: 无, 页码: 366-384
作者:  Wang, Qiang;  Liu, Feiyang;  Qi, Shuang;  Qi, Ziping;  Yan, Xiao-E.
  |  收藏  |  浏览/下载：62/0  |  提交时间：2019/06/10
Discovery of 4-Methyl-N-(44(4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)-3-((1-nicotinoylpiperidin-4-y1)oxy)benzamide (CHMFL-ABL/KIT-155) as a Novel Highly Potent Type II ABL/KIT Dual Kinase Inhibitor with a Distinct Hinge Binding 期刊论文  OAI收割
JOURNAL OF MEDICINAL CHEMISTRY, 2017, 卷号: 60, 期号: 1, 页码: 273-289
作者:  Wang, Qiang;  Liu, Feiyang;  Wang, Beilei;  Zou, Fengming;  Qi, Ziping
  |  收藏  |  浏览/下载：29/0  |  提交时间：2018/07/04
Discovery of N-((1-(4-(3-(3-((6,7-Dimethoxyquinolin-3-yl)oxy)phenyl)ureido)-2-(trifluoromethyl)phenyl)piperidin-4-yl)methyl)propionamide (CHMFL-KIT-8140) as a Highly Potent Type II Inhibitor Capable of Inhibiting the T670I "Gatekeeper" Mutant of cKIT Kinase 期刊论文  OAI收割
JOURNAL OF MEDICINAL CHEMISTRY, 2016, 卷号: 59, 期号: 18, 页码: 8456-8472
作者:  Li, Binhua;  Wang, Aoli;  Liu, Juan;  Qi, Ziping;  Liu, Xiaochuan
收藏  |  浏览/下载：38/0  |  提交时间：2017/11/21
Discovery of N-(34(1-lsonicotinoylpiperidin-4-yl)oxy)-4methylpheny1)-3-(trifluoromethyl)benzamide (CHMFL-KIT-110) as a Selective, Potent, and Orally Available Type II c-KIT Kinase Inhibitor for Gastrointestinal Stromal Tumors (GISTs) 期刊论文  OAI收割
JOURNAL OF MEDICINAL CHEMISTRY, 2016, 卷号: 59, 期号: 8, 页码: 3964-3979
作者:  Wang, Qang;  Liu, Feiyang;  Wang, Beilei;  Zou, Fengming;  Chen, Cheng
收藏  |  浏览/下载：14/0  |  提交时间：2017/11/10
Next Generation of Fluorine-Containing Pharmaceuticals, Compounds Currently in Phase II-III Clinical Trials of Major Pharmaceutical Companies: New Structural Trends and Therapeutic Areas 期刊论文  OAI收割
CHEMICAL REVIEWS, 2016, 卷号: 116, 期号: 2, 页码: 422-518
作者:  Zhou, Yu;  Wang, Jiang;  Gu, Zhanni;  Wang, Shuni;  Zhu, Wei
  |  收藏  |  浏览/下载：20/0  |  提交时间：2019/01/08